P4 Approach in Diabetes Type 2 (P4P-Hillegom)

The Impact of the P4 Approach, Preventive, Predictive, Personalized and Participatory in Newly Diagnosed Type 2 Diabetics in Hillegom

The study aims to assess the impact of the P4 approach on established markers of glucose metabolism in type 2 diabetics.

Secondary objectives are examination of the changes in physical characteristics, quality of life and the indices for beta cell function, hepatic insulin resistance and muscle insulin resistance .

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Behavioral: Intervention A: Diet; Behavioral: Intervention B: Exercise; Behavioral: Intervention C: Diet and Exercise

Detailed Description

This study will be a proof-of-principle exploratory study. Subjects in the P4 program will receive a personalized diagnosis and treatment. After investigation of the status of the different organs involved in diabetes (liver, muscle, pancreas), subjects in the P4 group are divided into 3 subgroups. Each subgroup receives a personalized lifestyle advice. This lifestyle advice may comprise different interventions, i.e. very low calorie diet, low calorie diet, strength training, endurance training. Dependent on the type of intervention, these interventions will be supervised by a dietitian or physiotherapist.

All subjects will visit a central study center 5 times during the study and 3 times during follow-up. During these visits physical measures will be taken and data will be collected by the general practitioner assistant.

After the three month intervention period the subjects will return to usual care via the general practitioner.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Utrecht
    • Zeist, Utrecht, Netherlands, 3704 HE
      • Netherlands Organisation for Applied Scientific Research (TNO)
  • Zuid Holland
    • Hillegom, Zuid Holland, Netherlands, 2181 EK
      • Huisartsenpraktijk Lommelaars
    • Hillegom, Zuid Holland, Netherlands, 2181 EN
      • Huisartspraktijk C.C. Dekker
    • Hillegom, Zuid Holland, Netherlands, 2181 EN
      • Huisartspraktijk Tubbergen
    • Hillegom, Zuid Holland, Netherlands, 2182 AA
      • Huisartsenpraktijk Sixlaan 9
    • Hillegom, Zuid Holland, Netherlands, 2182 CA
      • Huisartsenpraktijk J.G. van Dusseldorp
    • Hillegom, Zuid Holland, Netherlands, 2182 GP
      • Huisartsenpraktijk van der Kaaden
    • Hillegom, Zuid Holland, Netherlands, 2182 LN
      • Huisartsenpraktijk Elsbroek
    • Hillegom, Zuid Holland, Netherlands, 2182 VT
      • Huisartsenpraktijk Mulders

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy as assessed by the

   • health and lifestyle questionnaire, (P9607 F02; in Dutch)
   • physical examination
   • results of the pre-study laboratory tests
2. Age 30-80 years
3. Stable BMI 25-35 kg/m2

4. Diagnosis diabetes type 2 based upon:

   Fasting glucose >6.9 mmol/l on two different days or one measurement of non-fasting glucose >11.0 mmol/l in combination with symptoms of hyperglycemia

5. Duration of diabetes maximally 1 year
6. Informed consent signed;
7. Willing to comply with the study procedures during the study;
8. Appropriate veins for blood sampling/ cannula insertion according to the general practitioner assistant (GPA);
9. Voluntary participation
10. Physically able to perform training activities
11. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years.

Exclusion Criteria:

1. Use of insulin, corticosteroids (systemic), or beta-blockers in past month
2. Diabetes occurring after several attacks of pancreatitis known as pancreatic diabetes
3. Slow onset type 1 diabetes
4. Use of oral diabetes medication in past year
5. (Having a history of a) medical condition that might significantly affect the study outcome as judged by the medical investigator and health and life style questionnaire. This includes diabetes type 1, gastrointestinal dysfunction, diseases related to inflammation or allergy, or a psychiatric disorder.
6. Hypertension: systolic blood pressure >160 mmHg, diastolic blood pressure >90 mmHg
7. Kidney problems based upon proteinuria and creatinine >150 mmol/l
8. Insufficient beta cell function based on Disposition index < 1.5 as determined during the OGTT in study on day 01*
9. Physical activity higher than according to the Diabetes guidelines (moderate intensity one hour a day, seven days a week (overweight adults))
10. Alcohol consumption > 21 (women) - 28 (men) units/week
11. Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
12. Recent blood donation (<1 month prior to the start of the study)
13. Not willing to give up blood donation during the study
14. Personnel of TNO and their partner
15. Not having a general practitioner
16. Not willing to accept information-transfer concerning participation in the study, or information regarding his health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention A: Diet; Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).	Behavioral: Intervention A: Diet; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice; Other Names: very low calorie diet based on Modifast meal replacers.
Experimental: Intervention B: Exercise; Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes). Healthy isocaloric diet.	Behavioral: Intervention B: Exercise; subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
Experimental: Intervention C: Diet and Exercise; Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet. One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)	Behavioral: Intervention C: Diet and Exercise; subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.; Other Names: very low calorie diet based on Modifast meal replacers.
No Intervention: Control - Historical data; Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HbA1c levels	Changes in primary outcome measures will be determined by using a mixed model	In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months
Change in 2h glucose levels	2h glucose will be measured after Oral Glucose Tolerance Test (OGTT). Changes in primary outcome measures will be determined by using a mixed model	In-study at week 0 (baseline) and 13;
Change in fasting blood glucose levels	After 8 hour fasting. Changes in primary outcome measures will be determined by using a mixed model.	In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months
percentage of participants that reach normoglycemia	normoglycemia is determined by fasting blood glucose level of less than 6.1 mmol/L	end of study (after 13 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
body weight	measured by the general practitioner assistant	screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
blood pressure	measured by the general practitioner assistant	screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
waist circumference	measured by general practitioner assistant	screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
body fat percentage	measured by general practitioner assistant	screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months
change indices for muscle insulin resistance	at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data. Blood will be collected at the blood collection centre in Hillegom	screening; in-study at week 0 and 13;
health behaviour change	established by comparing baseline values with end of study values for food intake and physical activity as measured by a Lifestyle-questionnaire	in-study at week 0, 13; during follow-up at 6, 12 and 24 months
change in vitality as assessed with a vitality questionnaire (Vita-16)		in-study at week 0, 13; during follow-up at 6, 12 and 24 months
change in subjective quality of life as assessed with RAND-36 questionnaire		in-study at week 0, 13; during follow-up at 6, 12 and 24 months
change in indices for beta cell function	at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data. Blood will be collected at the blood collection centre in Hillegom	screening; in-study at week 0 and 13;
change in indices for hepatic insulin resistance	at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data. Blood will be collected at the blood collection centre in Hillegom	screening; in-study at week 0 and 13;

Collaborators and Investigators

• Sponsor: W.J. Pasman
• Investigators: Principal Investigator: Wilrike Pasman, PhD, Netherlands Organisation for Applied Scientific Research (TNO); Study Director: Peter van Dijken, Dr., Netherlands Organisation for Applied Scientific Research (TNO)

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2014
• Primary Completion (Actual): July 1, 2019
• Study Completion (Actual): July 1, 2019

Study Registration Dates

• First Submitted: July 16, 2014
• First Submitted That Met QC Criteria: July 18, 2014
• First Posted (Estimate): July 22, 2014

Study Record Updates

• Last Update Posted (Actual): October 25, 2019
• Last Update Submitted That Met QC Criteria: October 24, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Keywords: prevention; personalized treatment; improved diagnosis
• Other Study ID Numbers: P9607